Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls. The letter comes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback